A novel pyroptosis-related gene signature for predicting the prognosis of cervical cancer

Although morbidity has decreased in developed regions, cervical cancer (CC) continues to have the highest incidence of all gynecological malignancies. The burden of morbidity and mortality in developing regions is also rising quickly, especially for advanced CC. Along with apoptosis, iron death, and other forms of programmed cell death, pyroptosis is a significant inflammatory process. Its connection to the malignancy mechanism has been verified. The expression of genes linked to pyroptosis in CC tissue and its relationship to prognosis, however, remain poorly understood. Using The Cancer Genome Atlas, we first discovered 13 differentially expressed pyroptosis-related genes (DE-PRGs) in the study (TCGA). Based on DE-PRGs, CC patients were divided into four subtypes. The 4 parts’ times showed large variations according to the K-M curve. Then, using the least absolute shrinkage and selection operator (LASSO) Cox regression method, we created a mod el for predicting CC based on pyroptosis-associated genes. There were significant differences in overall survival (OS) times involving the high-risk and low-risk groups for all CC patients in the TCGA group, who were divided into low-risk and high-risk groups (p equals 0.0441). The risk score status as an independent prognostic factor for CC was confirmed by independent prognostic predictor validation. The analyses of single-sample gene set and enrichment analysis (ssGSEA), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) all revealed significant differences in immune cells and immune pathways involving high- and low-risk groups (p less than 0.001), indicating a weakened immune status in high-risk groups. In conclusion, pyroptosis-associated genes are involved in tumor immunity and can help determine a patient’s prognosis for CC. As a result, we have created and validated a signature that is related to pyroptosis and predicts CC prognosis, which may aid in early diagnosis, prognostic analysis, and immunotherapy.

Cervical cancer; Pyroptosis; Prognosis; Signature; Bioinformatics; TCGA

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Brodeur MN, Dejean R, Beauchemin MC, Samouëlian V, Cormier B, Bacha OM, et al. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer. Gynecologic Oncology. 2021; 162: 277–283.

[3] American Cancer Society. About cervical cancer. 2022. Available at: https://www.cancer.org/cancer/cervical-cancer/about/what-is-cervical-cancer.html (Accessed: 25 January 2022).

[4] Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. Journal of the National Medical Association. 2020; 112: 229–232.

[5] Chen H, Deng Q, Wang W, Tao H, Gao Y. Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer. Journal of Ovarian Research. 2020; 13: 131.

[6] Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomedicine & Pharmacotherapy. 2020; 121: 109595.

[7] Ye Y, Dai Q, Qi H. A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer. Cell Death Discovery. 2021; 7: 71.

[8] Lin W, Chen Y, Wu B, Chen Y, Li Z. Identification of the pyroptosisrelated prognostic gene signature and the associated regulation axis in lung adenocarcinoma. Cell Death Discovery. 2021; 7: 161.

[9] Chao B, Jiang F, Bai H, Meng P, Wang L, Wang F. Predicting the prognosis of glioma by pyroptosis-related signature. Journal of Cellular and Molecular Medicine. 2022; 26: 133–143.

[10] Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018; 173: 400–416.e11.

[11] Ruan J, Wang S, Wang J. Mechanism and regulation of pyroptosis-mediated in cancer cell death. Chemico-Biological Interactions. 2020; 323: 109052.

[12] Zheng Z, Li G. Mechanisms and therapeutic regulation of pyroptosis in inflammatory diseases and cancer. International Journal of Molecular Sciences. 2020; 21: 1456.

[13] Song J, Sun Y, Cao H, Liu Z, Xi L, Dong C, et al. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma. Bioengineered. 2021; 12: 5932–5949.

[14] Shao W, Yang Z, Fu Y, Zheng L, Liu F, Chai L, et al. The Pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer. Frontiers in Cell and Developmental Biology. 2021; 9: 676485.

[15] Zhou C, Li C, Zheng Y, Liu X. Identification of pyroptosis-related signature for cervical cancer predicting prognosis. Aging. 2021; 13: 24795–24814.

[16] Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, et al. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Molecular Cancer Research. 2013; 11: 1193–1202.

[17] Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, et al. Lack of absent in melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. International Journal of Cancer. 2014; 135: 2387–2396.

[18] Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, et al. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Molecular Cancer Therapeutics. 2006; 5: 1–7.

[19] Colarusso C, Terlizzi M, Lamort A, Cerqua I, Roviezzo F, Stathopoulos G, et al. Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma. Oncotarget. 2021; 12: 1057–1071.

[20] Zhang M, Jin C, Yang Y, Wang K, Zhou Y, Zhou Y, et al. AIM2 promotes non-small-cell lung cancer cell growth through inflammasome‐dependent pathway. Journal of Cellular Physiology. 2019; 234: 20161–20173.

[21] Dawson RE, Deswaerte V, West AC, Tang K, West AJ, Balic JJ, et al. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut. 2022; 71: 1515–1531.

[22] Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Kivisaari A, et al. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma. Oncotarget. 2017; 8: 45825–45836.

[23] So D, Shin H, Kim J, Lee M, Myeong J, Chun Y, et al. Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense. Oncogene. 2018; 37: 5191–5204.

[24] Hsu PC, Chao TK, Chou YC, Yu MH, Wang YC, Lin YH, et al. AIM2 inflammasome in tumor cells as a biomarker for predicting the treatment response to antiangiogenic therapy in epithelial ovarian cancer patients. Journal of Clinical Medicine. 2021; 10: 4529.

[25] Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nature Reviews Molecular Cell Biology. 2003; 4: 95–104.

[26] Kinoshita T, Wang Y, Hasegawa M, Imamura R, Suda T. PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1beta secretion. Journal of Biological Chemistry. 2005; 280: 21720–21725.

[27] Li B, Qi Z, He D, Chen Z, Liu J, Wong M, et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer. Journal of Experimental & Clinical Cancer Research. 2021; 40: 126.

[28] Ohno S, Kinoshita T, Ohno Y, Minamoto T, Suzuki N, Inoue M, et al. Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. Anticancer Research. 2008; 28: 2493–2497.

[29] Reynaud D, Abi Nahed R, Lemaitre N, Bolze PA, Traboulsi W, Sergent F, et al. NLRP7 promotes choriocarcinoma growth and progression through the establishment of an immunosuppressive microenvironment. Cancers. 2021; 13: 2999.

[30] Šutić M, Motzek A, Bubanović G, Linke M, Sabol I, Vugrek O, et al. Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC). Translational Lung Cancer Research. 2019; 8: 1000–1015.

[31] Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clinical Cancer Research. 2004; 10: 2000–2006.

[32] Collard RL, Harya NS, Monzon FA, Maier CE, O’Keefe DS. Methylation of the ASC gene promoter is associated with aggressive prostate cancer. The Prostate. 2006; 66: 687–695.

[33] Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, et al. Aberrant methylation ofTMS1 in small cell, non small cell lung cancer and breast cancer. International Journal of Cancer. 2003; 106: 198–204.

[34] Liang A, Zhong S, Xi B, Zhou C, Jiang X, Zhu R, et al. High expression of PYCARD is an independent predictor of unfavorable prognosis and chemotherapy resistance in glioma. Annals of Translational Medicine. 2021; 9: 986.

[35] Wang Z, Ni F, Yu F, Cui Z, Zhu X, Chen J. Prognostic significance of mRNA expression of CASPs in gastric cancer. Oncology Letters. 2019; 18: 4535–4554.

[36] Zhou Y, Dai W, Wang H, Pan H, Wang Q. Long non-coding RNA CASP5 promotes the malignant phenotypes of human glioblastoma multiforme. Biochemical and Biophysical Research Communications. 2018; 500: 966–972.

[37] Babas E, Ekonomopoulou MT, Karapidaki I, Doxakis A, Betsas G, Iakovidou-Kritsi Z. Indication of participation of caspase-2 and caspase-5 in mechanisms of human cervical malignancy. International Journal of Gynecological Cancer. 2010; 20: 1381–1385.

[38] Zhang Y, He R, Lei X, Mao L, Jiang P, Ni C, et al. A novel pyroptosis-related signature for predicting prognosis and indicating immune microenvironment features in osteosarcoma. Frontiers in Genetics. 2021; 12: 780780.

[39] Sha J, Du J, Yang J, Hu X, Li L. Changes of serum levels of tumor necrosis factor (TNF-α) and soluble interleukin-2 receptor (SIL 2R) in patients with cervical cancer and their clinical significance. American Journal of Translational Research. 2021; 13: 6599–6604.

[40] Behboodi N, Farazestanian M, Rastgar-Moghadam A, Mehramiz M, Karimi E, Rajabian M, et al. Association of a variant in the tumor necrosis factor alpha gene with risk of cervical cancer. Molecular Biology Reports. 2021; 48: 1433–1437.